Sahar Nosrati Shanjani

Passionate researcher in radiopharmaceutical sciences specializing in developing innovative radiolabeled compounds for disease diagnosis and treatment. Experienced in radiochemistry, including radiolabeling, quality control, and biodistribution studies. Committed to making a meaningful impact in healthcare through targeted therapies and nuclear medicine.

I am a dedicated professional with a strong background in radiopharmaceutical sciences and a passion for innovation in healthcare. My interests lie in molecular imaging, nanomedicine, drug discovery, and designing radiolabeled compounds for diagnostic and therapeutic purposes. Beyond work, I enjoy exploring new technologies, programming, and expanding my knowledge in cutting-edge scientific fields.

I’ve been recognized for my contributions to nuclear medicine research, including winning the Best Poster Award at the 19th Iranian Congress of Nuclear Medicine. My academic achievements include ranking third in the M.Sc. entrance exam for the Ministry of Health and Medical Education. I’m always eager to grow, collaborate, and contribute to impactful advancements in science and medicine.

Movies, Music, basketball, swimming, cooking, 

• 19th Iranian Congress of Nuclear Medicine, Conference, 09/16/15,Hamedan, Iran, Assessment of biodistribution dextran coated 70 nm iron oxide nanoparticles labeled with 68Ga for application in PET imaging (booklet)
• 20th Iranian Congress of Nuclear Medicine, Conference, 10/26/16,Mazandaran, Iran, Evaluation of biodistribution of DTPA-SPION
  radiolabeled with 166Hoin normal rat (booklet)
• International Symposium on Trends in Radiopharmaceuticals (ISTR- 2023), Conference, 04/17/23, Austri, Vienna, Radioiodinated anti-HER2
  monoclonalantibodies as potential therapeutic radiopharmaceuticals (attached file)
• International Conference on Development and Applications of Nuclear Technologies, Conference, 09/20/23, Kraków, Poland, Radioiodinated
  anti-HER2 monoclonal antibodies as potential therapeutic radiopharmaceuticals (attached file)
• NOMATEN International Radiopharmaceutical Conference, conference, 06/25/24, Warsaw, Poland, Radioiodinated anti-HER2
  monoclonal antibodies as potential therapeutic radiopharmaceuticals (attached file)
• NOMRad – NOMATEN International Radiopharmaceutical Conference, Conference, 06/25/24, Warsaw, Poland, The biodistribution and imaging
  studies: PEGylated superparamagnetic iron oxide nanoparticles labeled
  with 68Ga as a PET/MRI contrast agent (attached file)

• Development of 177Lu-DTPA-SPIO conjugates for potential use as a dual contrast SPECT/MRI imaging agent, Saeed Shanehsazzadeh, Cordula Grüttner, Hassan Yousefnia, Afsaneh Lahooti, Amir Gholami, Sahar Nosrati, Samaneh Zolghadri, Sayyed Hossein Mousavie Anijdan, Alireza Lotfabadi, Behrang Shiri Varnamkhasti, Fariba Johari Daha, Amir Reza Jalilian, Radiochimica Acta, 104, 5, 10.1515/ract-2015-2499
• Biodistribution evaluation of 166Ho– DTPA–SPION in normal rats, Sahar Nosrati, Saeed Shanehsazzadeh, Hassan Yousefnia, Amir Gholami, Cordula Grüttner, Amir Reza Jalilian, Reza Haji Hosseini, Afsaneh Lahooti, Journal of Radioanalytical and Nuclear Chemistry, 307, 2, 10.1007/s10967-015-4251-x
• PEGylated superparamagnetic iron oxide nanoparticles labeled with 68Ga as a PET/MRI contrast agent: a biodistribution study, Afsaneh Lahooti, Saeed Sarkar, Hamidreza Saligheh Rad, Amir Gholami, Sahar Nosrati, Robert N. Muller, Sophie Laurent, Cordula Grüttner, Parham Geramifar, Hassan Yousefnia, Mohammad Mazidi, Saeed Shanehsazzadeh, Journal of adioanalytical and Nuclear Chemistry, 311, 1, 10.1007/s10967-016-5058-0
• 99mTc radiolabeled imidazo[2,1-b]benzothiazole derivatives as potential radiotracers for glioblastoma, Sahar Nosrati, Sajjad Molavipordanjani,
  Saeed Emami, Seyed Mohammad Abedi, Fereshteh Talebpour Amiri, Seyed Jalal Hosseinimehr, Journal of Radioanalytical and Nuclear Chemistry, 323, 1, 10.1007/s10967-019-06945-4
• Potential utility of peptides against damage induced by ionizing radiation, Zahra Shaghaghi, Maryam Alvandi, Sahar Nosrati,Seyed Kamaledin Hadei, Future Oncology, 15, 35, 10.2217/fon-2020-0577